Who invested in ONL Therapeutics

3 rounds we have observed, with the 2 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$67Mraised across 3 rounds since 2014, from 3 sources

$502KSeed$1.4MGrant$65MSeries D

Latest round: Series D, $65MSept 2024
Step-upi: 47.4×
Investors: 2

See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

201420162018202020222024

$502KSeed$1.4MGrant$65MSeries D

First round: Seed, $502K
Biggest round: $65M
Usual gap between rounds: 9.8 years

The rounds

Sept 2024
Series D$65M2 new
- National Institutes of Health
- Novartis
Source recordedSEC filing: $60M sold, first sale Sept 2024
Nov 2014
Grant$1.4M
No investor was named in the report.
From a historical funding record
Jul 2014
Seed$502K
No investor was named in the report.
From a historical funding recordSEC filing: $502K sold, first sale Jun 2014

Founders and team

From ONL Therapeutics's own website: 7 on the team.

David EspositoPresident and Chief Executive Officer
Amanda MacielDirector of Finance
Anjalie MahabirProject Manager, Clinical Operations
Kristin HanleyLead Regulatory and Compliance Consultant
Linda KemnitzManager, Administrative Operations
Nicole RoseDirector, Clinical Operations
Rackham Graduate School2023 intern

Who was in which round

The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.

Seed2014Grant2014Series D2024

National Institutes of Health

Novartis

Everyone who backed them

National Institutes of HealthGovernment1round

NovartisVC firm1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

These 4 firms list ONL Therapeutics as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.